一项受31基因表达谱影响的前哨淋巴结活检决策后无复发生存率的前瞻性多中心分析
A Prospective, Multicenter Analysis of Recurrence-Free Survival After Sentinel Lymph Node Biopsy Decisions Influenced by the 31-GEP.
作者信息
Guenther J Michael, Ward Andrew, Martin Brian J, Cripe Mark, Beard Timothy, Wisco Oliver, Sharma Rohit, Leong Stanley P, Essner Richard, Clark Joseph I, Hamner John, Sickle-Santanello Brenda, Yamamoto Maki
机构信息
St Elizabeth Physicians General & Vascular Surgery, Edgewood, Kentucky, USA.
University of Tennessee Medical Center, Knoxville, Tennessee, USA.
出版信息
Cancer Med. 2025 Apr;14(7):e70839. doi: 10.1002/cam4.70839.
BACKGROUND
Although most patients with cutaneous melanoma (CM) will have a negative sentinel lymph node biopsy (SLNB), up to 20%-30% of these patients will recur. The 31-gene expression profile (31-GEP) test has been prospectively validated to identify patients at low (Class 1A), intermediate (Class 1B/2A), and high (Class 2B) risk of SLN positivity and recurrence.
METHODS
DECIDE is a prospective, multicenter study to assess the effect of 31-GEP testing on SLNB performance rates in patients with T1-T2 tumors considering SLNB and to study long-term outcomes. Here, we assessed outcomes in patients with a Class 1A 31-GEP result (n = 130).
RESULTS
Of Class 1A patients, 63 had an SLNB, with a 3.2% SLN positivity rate (2/63). No Class 1A patients, regardless of SLN status, experienced a recurrence (2-year median follow-up).
CONCLUSIONS
These results are consistent with previous studies that showed the 31-GEP can identify patients at low risk of SLN positivity and recurrence.
背景
尽管大多数皮肤黑色素瘤（CM）患者前哨淋巴结活检（SLNB）结果为阴性，但这些患者中仍有20%-30%会复发。31基因表达谱（31-GEP）检测已得到前瞻性验证，可用于识别前哨淋巴结阳性和复发风险低（1A类）、中（1B/2A类）、高（2B类）的患者。
方法
DECIDE是一项前瞻性多中心研究，旨在评估31-GEP检测对考虑进行SLNB的T1-T2期肿瘤患者SLNB执行率的影响，并研究长期结局。在此，我们评估了31-GEP结果为1A类的患者（n = 130）的结局。
结果
在1A类患者中，63例进行了SLNB，前哨淋巴结阳性率为3.2%（2/63）。无论前哨淋巴结状态如何，均无1A类患者出现复发（中位随访2年）。
结论
这些结果与先前的研究一致，表明31-GEP可识别前哨淋巴结阳性和复发风险低的患者。
Zotero 插件